<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Institute of Human Genetics</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D7CE8CDA-BF66-40E8-8449-884BBC6ED7FD"><gtr:id>D7CE8CDA-BF66-40E8-8449-884BBC6ED7FD</gtr:id><gtr:firstName>Neil</gtr:firstName><gtr:surname>Rajan</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701367"><gtr:id>87CEC5F3-B779-4E7B-A019-3CD2C5C24656</gtr:id><gtr:title>Familial Cylindromatosis: Identification of tumourigenic pathways and drug targets in human tissue.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0701367</gtr:grantReference><gtr:abstractText>Aims
To define the pathways involved in tumour formation, and to target these pathways with novel, preclinical agents. 

Objectives: 

1) To identify pathways in cylindroma formation by: 
a) Gene expression profiling of human cylindroma tissue, to identify the key regulatory pathways, abrogation of which are associated with tumourigenesis.
b) To confirm the gene expression microarray results by secondary techniques, namely, immunohistochemistry, quantitative PCR and Western blot analysis.

2) The development of a primary cylindroma cell line:
a) To allow the investigation of biological functions of novel therapeutically relevant pathways, as highlighted by the array data. 
b) To be the basis of a drug-screening assay to test preclinical agents that target the abrogated pathways defined above.

The ultimate goal will be to begin clinical trials of non-surgical treatments in FC, to improve quality of life, prognosis, and outcome.</gtr:abstractText><gtr:technicalSummary>Aims
To define the pathways involved in tumour formation, and to target these pathways with novel, preclinical agents. 

Objectives: 

1) To identify pathways in cylindroma formation by: 
a) Gene expression profiling of human cylindroma tissue, to identify the key regulatory pathways, abrogation of which are associated with tumourigenesis.
b) To confirm the gene expression microarray results by secondary techniques, namely, immunohistochemistry, quantitative PCR and Western blot analysis.

2) The development of a primary cylindroma cell line:
a) To allow the investigation of biological functions of novel therapeutically relevant pathways, as highlighted by the array data. 
b) To be the basis of a drug-screening assay to test preclinical agents that target the abrogated pathways defined above.

The ultimate goal will be to begin clinical trials of non-surgical treatments in FC, to improve quality of life, prognosis, and outcome.</gtr:technicalSummary><gtr:fund><gtr:end>2010-06-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-06-02</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>134648</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with Alan Ashworth</gtr:description><gtr:id>574BC9A8-BC41-4D2B-A43D-D0EE0F71F5F4</gtr:id><gtr:impact>The data from this collaboration has led to the development of two papers. One is under review and the other is due to be submitted.</gtr:impact><gtr:outcomeId>JS55m7W4aA8-1</gtr:outcomeId><gtr:partnerContribution>Access to facilities and technologies at Breakthrough; training ; supporting costs of microarray experiements</gtr:partnerContribution><gtr:piContribution>Accessing rare tumour tissue from surgery on patients with CYLD mutations; microdissecting this tissue and extracting RNA; performing transcriptomic profiling experiments. Bioinformatic analysis of the microarray data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Karolinska Institute</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>Department of Medicine, Solna</gtr:department><gtr:description>Karolinska</gtr:description><gtr:id>311D0E3D-AE2E-4AA2-96AB-C03A65292DDB</gtr:id><gtr:impact>In progress</gtr:impact><gtr:outcomeId>fNsfaYbRJ3N-1</gtr:outcomeId><gtr:partnerContribution>Novel assays supplied to profile RNA changes in skin tumours</gtr:partnerContribution><gtr:piContribution>Exploring RNA species in CYLD defective tumours</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>MRC Max Perutz Science writing prize</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DA82C623-6839-4057-BFEB-BB9856ACB145</gtr:id><gtr:impact>I entered a competition in science writing that won highly commended for being novel and different.

Published on MRC website, this work is available to the public. It raised the profile of the sponsoring institute and local interest in cutaneous tumour biology.</gtr:impact><gtr:outcomeId>GDpA88w6HrY</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Hosting A-Level students</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>08726149-F417-43FD-ABB1-FA47485164CE</gtr:id><gtr:impact>Currently hosting an A-level student with an interest in medicine and genetics for a placement over a 6-week period to get a taster of laboratory life.

Not assessable at this stage</gtr:impact><gtr:outcomeId>iy22SWcaJWm</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Develop and support a patient group for CYLD mutation carriers</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D3AE2DAF-4403-4169-9130-60B68788D16C</gtr:id><gtr:impact>This has led to a rolling programme of patient support group meetings.

A patient information leaflet on living with multiple cylindromas is being created in partnership with the patient group</gtr:impact><gtr:outcomeId>KzAhNuAwo4Y</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>521217</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Health Innovation Challenge Fund</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>572EAE8F-9028-4A52-BDA9-46704E57D240</gtr:id><gtr:outcomeId>FZEuK8Mof1Y</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>785000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Intermediate Clinical Fellowship</gtr:description><gtr:end>2016-05-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>WT097163MA</gtr:fundingRef><gtr:id>1A00EA16-C384-4CA3-B3F0-1947B7016E40</gtr:id><gtr:outcomeId>cZQCp44QUBE</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>A review of seven U.K. pedigrees with CYLD mutations: Clinical implications for mutation carriers.</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>8E376A4E-A07F-4972-B9B1-77618B2C0387</gtr:id><gtr:outcomeId>9B0E64C174C</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Genetics of Skin Cancer</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Rare Skin Cancer Syndromes-Brooke-Spiegler Syndrome, Multiple Familial Trichoepithelioma, and Familial Cyndromatosis</gtr:guidelineTitle><gtr:id>338D1F73-FF05-479C-B1EE-4698F9B72FD9</gtr:id><gtr:impact>Improved understanding of the clinical phenotype of CYLD mutation carriers influences the management of this disease.</gtr:impact><gtr:outcomeId>ieUbCydP5rh</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.cancer.gov/cancertopics/pdq/genetics/skin/HealthProfessional/page5</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>An output of the transcriptomic profiling of CYLD defective tumours is that TRK signalling is dysregulated in these tumours.I have recently secured funding (WT/DOH - HICF)to investigate the use of a topical TRK inhibitor in CYLD mutation carriers.</gtr:description><gtr:id>494DB533-7763-4943-8EE6-B1CE14B48E01</gtr:id><gtr:impact>The prospect of non-surgical treatments for this disfiguring disease has prompted the development of a registry of UK CYLD mutation carriers.</gtr:impact><gtr:outcomeId>FSBqpwUxbrS</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Targeting TRK in CYLD mutation carriers</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Transcriptomes of 32 CYLD defective tumours and 10 perilesional controls. This resource has been useful to understand the consequence of loss of functional CYLD in a cutaneous tumour model</gtr:description><gtr:id>14886E9A-33A2-4E99-854B-016E67CDC1CA</gtr:id><gtr:impact>Validation of dysregulated Wnt signalling in a human tumour model mediated by loss of functional CYLD .</gtr:impact><gtr:outcomeId>XtJoXQZWjmd</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Whole genome expression profilling data of CYLD defectve tumours</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Primary cultures derived from CYLD defective tumours</gtr:description><gtr:id>4876FD22-5628-41C0-AEB6-751A4BC261DA</gtr:id><gtr:impact>Functional analysis of targeting dysregulated pathways in CYLD defective tumours, including the use of these cells for drug discovery</gtr:impact><gtr:outcomeId>pLP1fn7Qa1S</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>CYLD defective tumour primary cell culture</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B12102A7-3440-4E10-B3F5-27226716DCCA</gtr:id><gtr:title>Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c45e85632b5d6317894574a73ef9523"><gtr:id>5c45e85632b5d6317894574a73ef9523</gtr:id><gtr:otherNames>Rajan N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>pm_540e158e15829d205</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>807E380E-FFD4-4D25-8A5A-A8BFDB893D12</gtr:id><gtr:title>Transition from cylindroma to spiradenoma in CYLD-defective tumours is associated with reduced DKK2 expression.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c45e85632b5d6317894574a73ef9523"><gtr:id>5c45e85632b5d6317894574a73ef9523</gtr:id><gtr:otherNames>Rajan N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>ETKSQZNYfMV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E66E453E-0848-41EF-9173-F9E2BEE661B3</gtr:id><gtr:title>The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate notch signalling.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c45e85632b5d6317894574a73ef9523"><gtr:id>5c45e85632b5d6317894574a73ef9523</gtr:id><gtr:otherNames>Rajan N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>545cd6d7a92864.01625317</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD89F1E9-BFFF-4B68-9573-81C58CEB0C6F</gtr:id><gtr:title>Tumor mapping in 2 large multigenerational families with CYLD mutations: implications for disease management and tumor induction.</gtr:title><gtr:parentPublicationTitle>Archives of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c45e85632b5d6317894574a73ef9523"><gtr:id>5c45e85632b5d6317894574a73ef9523</gtr:id><gtr:otherNames>Rajan N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0003-987X</gtr:issn><gtr:outcomeId>B586020BD43</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701367</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>